RECURSION PHARMACEUTICALS, INC. Deferred Revenue Recognized
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Deferred Revenue Recognized of $7.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. contract with customer, liability, revenue recognized for the quarter ending 2026-06-30 was $7.00M, a 54.55% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $4.40M, a 70.07% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was $4.50M, a 9.76% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. contract with customer, liability, revenue recognized for the quarter ending 2025-06-30 was $15.40M, a 36.28% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. contract with customer, liability, revenue recognized for fiscal 2025 was $52.10M, a 60.31% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. contract with customer, liability, revenue recognized for fiscal 2024 was $32.50M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 3 month as first filed | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 6 month as first filed | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7.00M 10-Q · filed 2026-08-05 | $11.40M 10-Q · filed 2026-08-05 | ||||
| 2026-03-31 | $4.40M 10-Q · filed 2026-05-06 | |||||
| 2025-12-31 | $52.10M 10-K · filed 2026-02-25 | |||||
| 2025-09-30 | $4.50M 10-Q · filed 2025-11-05 | $36.60M 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | $15.40M 10-Q · filed 2026-08-05 | $30.20M 10-Q · filed 2026-08-05 | ||||
| 2025-03-31 | $14.70M 10-Q · filed 2026-05-06 | |||||
| 2024-12-31 | $32.50M 10-K · filed 2025-02-28 | |||||
| 2024-09-30 | $4.10M 10-Q · filed 2025-11-05 | $29.00M 10-Q · filed 2025-11-05 | ||||
| 2024-06-30 | $11.30M 10-Q · filed 2025-08-05 | $25.00M 10-Q · filed 2024-08-08 | $25.00M 10-Q · filed 2025-08-05 | $11.30M 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | $13.50M 10-Q · filed 2025-05-05 | |||||
| 2022-03-31 | $2.50M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |